VIM
SRPT icon

VELA Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

VELA Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,788
Closed -$269K – 176
2023
Q4 		$269K Hold
2,788
– – 0.1% 150
2023
Q3 		$338K Hold
2,788
– – 0.15% 122
2023
Q2 		$319K Buy
2,788
+694
+33% +$89.5K 0.15% 125
2023
Q1 		$289K Buy
+2,094
New +$272K 0.13% 128

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VELA Investment Management's SRPT Position: Q1 2024 in Review

VELA Investment Management sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 2,788 shares — an estimated $269K sold.

VELA Investment Management first reported a position in SRPT in Q1 2023 and held it in 4 quarters. The position peaked at $338K in Q3 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • VELA Investment Management reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • VELA Investment Management sold 2,788 Sarepta Therapeutics shares in Q1 2024, an estimated $269K.
  • VELA Investment Management first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 4 quarters.
  • VELA Investment Management's Sarepta Therapeutics position peaked at $338K in Q3 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on VELA Investment Management's 13F filing for Q1 2024, filed 13 May 2024.